Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)

被引：0
|
作者：
Beal, K. [1 ]
Omuro, A. [1 ]
Karimi, S. [1 ]
Correa, D. [1 ]
Chan, T. A. [1 ]
DeAngelis, L. M. [1 ]
Yamada, Y. [1 ]
Abrey, L. E. [1 ]
Gutin, P. H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [21] NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress
    Khasraw, Mustafa
    McDonald, Kerrie L.
    Yip, Sonia
    Verhaak, Roel
    Heimberger, Amy
    Hall, Merryn
    Fisher, Lauren
    Barnes, Elizabeth
    Rosenthal, Mark
    Gedye, Craig
    Hovey, Elizabeth
    Ellingson, Benjamin M.
    Simes, John
    Tongela, Annette
    Wheeler, Helen
    Koh, Eng-Siew
    Gan, Hui
    Back, Michael
    Lwin, Zarnie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 197
  • [22] DIFFUSION AND PERFUSION MAGNETIC RESONANCE IMAGING IN NEWLY DIAGNOSED GLIOBLASTOMA FOLLOWING TREATMENT WITH BEVACIZUMAB, TEMOZOLOMIDE AND HYPO-FRACTIONATED STEREOTACTIC RADIOTHERAPY (HFSRT)
    Daras, Mariza
    Karimi, Sasan
    Abrey, Lauren
    Sanchez, Juan
    Beal, Kathryn
    Gutin, Philip
    Kaley, Thomas
    Grommes, Christian
    Correa, Denise
    Reiner, Anne
    Briggs, Samuel
    Omuro, Antonio
    NEURO-ONCOLOGY, 2013, 15 : 194 - 194
  • [23] Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
    Grossman, S. A.
    Ye, X.
    Chamberlain, M. C.
    Mikkelsen, T.
    Batchelor, T. T.
    Desideri, S.
    Piantadosi, S.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
    Thomas, Alissa A.
    Beal, Kathryn
    McNeill, Katharine Anne
    Kaley, Thomas Joseph
    DeAngelis, Lisa Marie
    Mellinghoff, Ingo K.
    Diamond, Eli L.
    Chan, Timothy An-thy
    Young, Robert J.
    Perez, Julio Arevalo
    Yamada, Yoshiya
    Anderson, Barry Douglas
    Lamson, Michael
    Burch, Brandon
    Karmali, Rashida A.
    Omuro, Antonio Marcilio Padula
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
    Omuro, Antonio Marcilio Padula
    Beal, Kathryn
    McNeill, Katharine Anne
    Thomas, Alissa A.
    Lin, Xuling
    Kaley, Thomas Joseph
    DeAngelis, Lisa Marie
    Mellinghoff, Ingo K.
    Diamond, Eli L.
    Chan, Timothy An-thy
    Young, Robert J.
    Yamada, Yoshiya
    Gorman, Greg
    Lamson, Michael
    Bavisotto, Linda M.
    Karmali, Rashida A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
    Saran, Frank
    Welsh, Liam
    James, Allan
    McBain, Catherine
    Gattamaneni, Rao
    Jefferies, Sarah
    Harris, Fiona
    Cseh, Agnieszka
    Pemberton, Karine
    Schaible, Jennifer
    Bender, Shaun
    Brada, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2012, 14 : 79 - 79
  • [28] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Supriya Mallick
    Haresh Kunhiparambath
    Subhash Gupta
    Rony Benson
    Seema Sharma
    M. A. Laviraj
    Ashish Datt Upadhyay
    Pramod Kumar Julka
    Dayanand Sharma
    Goura Kishor Rath
    Journal of Neuro-Oncology, 2018, 140 : 75 - 82
  • [29] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Mallick, Supriya
    Kunhiparambath, Haresh
    Gupta, Subhash
    Benson, Rony
    Sharma, Seema
    Laviraj, M. A.
    Upadhyay, Ashish Datt
    Julka, Pramod Kumar
    Sharma, Dayanand
    Rath, Goura Kishor
    JOURNAL OF NEURO-ONCOLOGY, 2018, 140 (01) : 75 - 82
  • [30] EXTENT OF CEREBRAL RADIONECROSIS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED ON A CLINICAL TRIAL WITH HYPOFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY (HYPO-IMRT) COMBINED WITH TEMOZOLOMIDE (TMZ) AND BEVACIZUMAB (BEV)
    Ney, Douglas
    Kleinschmidt-DeMasters, B. K.
    Carlson, Julie
    Damek, Denise
    Gaspar, Laurie
    Kavanagh, Brian
    Waziri, Allen
    Lillehei, Kevin
    Reddy, Krishna
    Chen, Changhu
    NEURO-ONCOLOGY, 2014, 16
12345